GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

Dominari Holdings DOMH · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.15

-17.86%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Dominari Holdings

From its filings with the US Securities and Exchange Commission

SEC filings

Dominari Holdings is based in New York, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker DOMH. The SEC classifies its business as security brokers, dealers & flotation companies. In the fiscal year to 31 December 2025, it reported revenue of $123.1m and a net loss of $22.4m. At that date it held total assets of $112.9m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
18 Mar 1980
Employees
7
Head office
725 FIFTH AVENUE, NEW YORK, NY, 10022
Incorporated in
DE
Classification
Security Brokers, Dealers & Flotation Companies
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Anthony HayesChairman of the Board, Chief Executive Officer, since 2013$2.8m
  • Mr. Kyle WoolPresident, Director; Chief Executive Officer of Dominari Financial Inc, since 2021$2.8m
  • Mr. Timothy LedwickChief Financial Officer, since 2015$65,000
  • Mr. Christopher DevallChief Operating Officer$272,601
  • Ms. Soo YuSpecial Projects Manage, since 2022$2.4m
  • Mr. Brian ParsleyDirector
  • Mr. Gregory BlattnerIndependent Director$65,000
  • Mr. Robert DudleyIndependent Director$65,000
  • Mr. Kyle HaugIndependent Director$65,000
  • Mr. Brett MaasManaging Partner, Hayden IR, since 2022

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Dominari Holdings Inc employs 7 full-time employees in biotechnology development.
  • Dominari Securities LLC provides wealth management and investment banking services.
  • Dominari's antiviral platform targets multiple viruses including SARS-CoV-2 and Influenza.

Weaknesses

  • Dominari Holdings has only 7 full-time employees in a complex biotechnology sector.
  • Dominari's financial services subsidiaries operate in a highly competitive market.
  • Dominari's biotechnology R&D requires significant capital investment.

Opportunities

  • Dominari's antiviral platform could expand into emerging markets for pandemic response.
  • Dominari Securities LLC can leverage its investment banking services for high-growth industries.
  • Dominari's biotechnology portfolio may attract partnerships in the Health Care sector.

Threats

  • Dominari's small team size may hinder rapid development in biotechnology.
  • Dominari's financial services face regulatory challenges in the US market.
  • Dominari's antiviral platform faces competition from established pharmaceutical companies.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.